Technical Analysis for EGRX - Eagle Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 64.78 -0.11% -0.07
EGRX closed down 0.11 percent on Friday, February 16, 2018, on 89 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
3 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical EGRX trend table...

Date Alert Name Type % Chg
Feb 16 Shooting Star Candlestick Bearish 0.00%
Feb 16 Lizard Bearish Bearish Day Trade Setup 0.00%
Feb 16 Doji - Bearish? Reversal 0.00%
Feb 16 Upper Bollinger Band Walk Strength 0.00%
Feb 16 Wide Bands Range Expansion 0.00%
Feb 16 Above Upper BB Strength 0.00%
Feb 16 Overbought Stochastic Strength 0.00%
Feb 15 Upside 200 DMA Break Bullish -0.11%
Feb 15 Expansion Breakout Bullish Swing Setup -0.11%
Feb 15 Stochastic Reached Overbought Strength -0.11%

Older signals for EGRX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was founded in 2007 and is based in Woodcliff Lake, New Jersey.
Is EGRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 97.15
52 Week Low 45.05
Average Volume 221,193
200-Day Moving Average 62.6094
50-Day Moving Average 58.5164
20-Day Moving Average 59.979
10-Day Moving Average 59.95
Average True Range 2.7586
ADX 16.09
+DI 28.51
-DI 15.9
Chandelier Exit (Long, 3 ATRs ) 57.7742
Chandelier Exit (Short, 3 ATRs ) 62.0458
Upper Bollinger Band 64.347
Lower Bollinger Band 55.611
Percent B (%b) 1.05
BandWidth 14.565098
MACD Line 1.0401
MACD Signal Line 0.4572
MACD Histogram 0.5829
Fundamentals Value
Market Cap 982.64 Million
Num Shares 15.2 Million
EPS 5.96
Price-to-Earnings (P/E) Ratio 10.87
Price-to-Sales 3.34
Price-to-Book 4.96
PEG Ratio 0.95
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 67.23
Resistance 3 (R3) 67.38 66.71 66.82
Resistance 2 (R2) 66.71 66.09 66.64 66.68
Resistance 1 (R1) 65.75 65.71 66.23 65.60 66.55
Pivot Point 65.08 65.08 65.33 65.01 65.08
Support 1 (S1) 64.12 64.46 64.60 63.97 63.01
Support 2 (S2) 63.45 64.08 63.38 62.88
Support 3 (S3) 62.49 63.45 62.74
Support 4 (S4) 62.34